drugset / Trial / NCT04189848
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.
Timeline
- Start
- 2019-12-03
- Primary completion
- 2020-01-29
- Completion
- 2020-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 0.25 mg | Subcutaneous |